Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity

T cells expressing high avidity T-cell receptors (TCRs) have been shown to mediate superior therapeutic effects. A novel k(off)-rate assay allows for the quantitative and reproducible assessment of the avidity of TCRs for their ligands directly on living T cells, ex vivo. This assay might facilitate...

Descripción completa

Detalles Bibliográficos
Autores principales: Weissbrich, Bianca, Nauerth, Magdalena, Busch, Dirk H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825721/
https://www.ncbi.nlm.nih.gov/pubmed/24244903
http://dx.doi.org/10.4161/onci.26199
_version_ 1782290837712928768
author Weissbrich, Bianca
Nauerth, Magdalena
Busch, Dirk H
author_facet Weissbrich, Bianca
Nauerth, Magdalena
Busch, Dirk H
author_sort Weissbrich, Bianca
collection PubMed
description T cells expressing high avidity T-cell receptors (TCRs) have been shown to mediate superior therapeutic effects. A novel k(off)-rate assay allows for the quantitative and reproducible assessment of the avidity of TCRs for their ligands directly on living T cells, ex vivo. This assay might facilitate the selection of T cells with an optimal avidity for their target, hence favoring the development of adoptive immunotherapeutic regimens.
format Online
Article
Text
id pubmed-3825721
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38257212013-11-15 Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity Weissbrich, Bianca Nauerth, Magdalena Busch, Dirk H Oncoimmunology Author's View T cells expressing high avidity T-cell receptors (TCRs) have been shown to mediate superior therapeutic effects. A novel k(off)-rate assay allows for the quantitative and reproducible assessment of the avidity of TCRs for their ligands directly on living T cells, ex vivo. This assay might facilitate the selection of T cells with an optimal avidity for their target, hence favoring the development of adoptive immunotherapeutic regimens. Landes Bioscience 2013-10-01 2013-09-12 /pmc/articles/PMC3825721/ /pubmed/24244903 http://dx.doi.org/10.4161/onci.26199 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Weissbrich, Bianca
Nauerth, Magdalena
Busch, Dirk H
Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity
title Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity
title_full Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity
title_fullStr Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity
title_full_unstemmed Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity
title_short Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity
title_sort adoptive immunotherapy: new assay for the identification of t cells with optimal avidity
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825721/
https://www.ncbi.nlm.nih.gov/pubmed/24244903
http://dx.doi.org/10.4161/onci.26199
work_keys_str_mv AT weissbrichbianca adoptiveimmunotherapynewassayfortheidentificationoftcellswithoptimalavidity
AT nauerthmagdalena adoptiveimmunotherapynewassayfortheidentificationoftcellswithoptimalavidity
AT buschdirkh adoptiveimmunotherapynewassayfortheidentificationoftcellswithoptimalavidity

Ejemplares similares